Takeda
About Takeda
1547 articles about Takeda
-
Takeda Announces Third-Quarter FY2023 Results；On Track Towards Full-Year Management Guidance With Strong Momentum in Growth&Launch Products 2/1/2024 Takeda announced financial results for the third quarter of fiscal year2023.With year-to-date strong momentum in its Growth&Launch Products offsetting the significant revenue impact of generic entrants，Takeda remains on track towards its full-year Management Guidance。 -
Takeda and Protagonist Therapeutics，Inc.Enter into Worldwide License and Collaboration Agreement for Rusfertide，a Late-Stage Rare Hematology Asset 1/31/2024 Takeda and Protagonist Therapeutics，Inc。 -
Tome Biosciences Appoints Industry Veteran Daniel Curran，MD，to its Board of Directors 1/30/2024 Tome Biosciences，Inc.，the programmable genomic integration company，announces the appointment of Daniel Curran，MD，to its Board of Directors。 -
Takeda’s GAMMAGARD LIQUID®Approved by U.S.FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy（CIDP） 1/29/2024 Takeda（TSE:45002/NYSE:TAK）today announced that the U.S.Food and Drug Administration（FDA）has approved GAMMAGARD LIQUID ® [Immune Globulin Infusion（Human）10%solution]asan intravenous immunoglobulin（IVIG）therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy（CIDP）。 -
Takeda’s HYQVIA®Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy（CIDP） 1/29/2024 Takeda announced that the European Commission approved HYQVIA®[Immune Globulin Infusion 10%with Recombinant Human Hyaluronidas maintenance therapy in patients of allages with chronic inflammatory demyelinating polyneuropathy after stabilization with intravenous immunogloblin therapy。 -
工程辅助建模基础设施和应用程序管理部件的数字转换 1/25/2024 Cognizant announced an expanded agreement with Takeda，aglobal biopharmaceutical company，to support the company's digital transformation strategy by reinforcing and supporting its technology efforts。 -
Seventh Conceutive Yer为Takeda Named Global Top Employer 1/18/2024 Takeda （TSE:45002/NYSE:TAK）today announced that for the seventh consecutive year，it has received global Top Employer®certification for 2024。 -
The FDA on Tuesday extended the label for Takeda’s immune globulin infusion as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy。 -
Speaking to BioSpace in San Francisco，Elena Koundourakis，the head of the orexin franchise at Takeda Pharmaceuticals，gave a preview of what is ahead for its aims to treat narcolepsy。 -
Adimab Provides2023 Update on Clinical Pipeline 1/9/2024 Adimab，LLC today announced that12new partner programs entered clinical development in 2023。 -
Amid the Biden administration’s efforts to reduce drug prices，Reuters reported in anexclusive that several pharmaceutical companies will raise pharma prices in January 2024。 -
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration 12/21/2023 JCR Pharmaceuticals Co.，Ltd.announced today that Takeda Pharmaceutical Co.，Ltd.（“Takeda”）decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses（AAV）combined with the JCR J-Brain Cargo ®Technology。 -
Takeda Announces China NMPA Approval of LIVTENCITY®（maribavir）for the Treatment of Adults With Post-transplant Cytomegalovirus（CMV）Refractory to Prior Therapies 12/21/2023 Takeda（TSE:45002/NYSE:TAK）today announced that LIVTENCITY ® （maribavir）has been approved by the National Medical Products Administration（NMPA）of China for the treatment of adult patients with post-hematopoietic stem cell transplant（HSCT）or solid organ transplant（SOT）cytomegalovirus（CMV）infection/disease that is refractory to treatment（with）ganciclovir， valganciclovir，cidofovir or foscarnet。 -
为GLASSIA Treatment for Rare for Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA Treatment for Rare for of Emphysema 12/20/2023 Takeda Canada Inc.（Takeda）has entered into a contract with Canadian Blood Services（CBS）for GLASSIA ® （alpha-1proteinase inhibitor）resulting from CBS's request for proposal for hereditary deficiency of Alpha-1Antitrypsin Deficiency（Alpha-1）。 -
TYQVIA®as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy（CIDP） 12/15/2023 Takeda（TSE:45002/NYSE:TAK）today announced the European Medicines Agency’s（EMA）Committee for Medicinal Products for Human使用（CHMP）has recommended the approval of HYQVIA ® [Immune Globulin Infusion10%（Human）with Recombinant Human HumanHuluronidase]in patients with chronic inflammatory demyelinating polyneuropathy（CIDP）as maintenance therapy after stabilization with intravenous immunoglobulin therapy（IVIG）。 -
Takeda to Present Data at65 th American Society of Hematology（ASH）Annual Meeting， 不可拆卸的、可拆卸的、可拆卸的、可拆卸的、可拆卸的、可拆卸的、可拆卸的 11/27/2023 Takeda to Present Data at65 th American Society of Hematology（ASH）Annual Meeting， Demonstrating Continued Commitment to Patients with Hematologic Diseases。 -
ADAMTS13， Recombinant-krhn），a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder 11/20/2023 Orsini Specialty Pharmacy has been selected by Takeda Pharmaceuticals as the exclusive specialty pharmacy partner for ADZYNMA（ADAMTS13，recombinant-krhn）。 -
The biopharma’s Adzynma，ahumn recombinant ADAMST13therapeutic，is the first approved therapy for the ultra-rare clotting disorder congenital thrombotic thrombocytopenic purpura。 -
Takeda’s ADZYNMA（ADAMTS13，recombinant-krhn）Approved by U.S.FDA as the First and Only Recommbinant ADAMTS13Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura（cTTP） 11/9/2023 Takeda announced that the U.S.Food and Drug Administration has approved ADZYNMA for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura。 -
The oral targeted therapy，now sold under the brand name Fruzaqla，is approved for adults with metatic colorectal cancer who have received certain previous treatments for the disease。